U.S. markets open in 2 hours 9 minutes
  • S&P Futures

    3,996.00
    +19.25 (+0.48%)
     
  • Dow Futures

    32,237.00
    +161.00 (+0.50%)
     
  • Nasdaq Futures

    11,973.25
    +31.00 (+0.26%)
     
  • Russell 2000 Futures

    1,809.90
    +13.10 (+0.73%)
     
  • Crude Oil

    111.30
    +0.97 (+0.88%)
     
  • Gold

    1,842.70
    -3.60 (-0.19%)
     
  • Silver

    21.92
    +0.05 (+0.21%)
     
  • EUR/USD

    1.0718
    +0.0033 (+0.31%)
     
  • 10-Yr Bond

    2.7490
    0.0000 (0.00%)
     
  • Vix

    28.20
    -1.25 (-4.24%)
     
  • GBP/USD

    1.2615
    +0.0037 (+0.29%)
     
  • USD/JPY

    126.9590
    -0.2820 (-0.22%)
     
  • BTC-USD

    28,997.09
    -643.80 (-2.17%)
     
  • CMC Crypto 200

    634.53
    -36.47 (-5.44%)
     
  • FTSE 100

    7,523.03
    +0.28 (+0.00%)
     
  • Nikkei 225

    26,604.84
    -72.96 (-0.27%)
     

Why Sierra Oncology Stock Is On Fire Today

·2 min read
Why Sierra Oncology Stock Is On Fire Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of the clinical-stage biotech Sierra Oncology (NASDAQ: SRRA) jumped by as much as 90% in premarket trading Tuesday. Investors are piling into this small-cap biotech stock today in response to overwhelmingly positive late-stage trial results for the blood cancer drug candidate momelotinib. Specifically, Sierra announced ahead of the opening bell Tuesday morning that momelotinib met all of its primary and secondary endpoints in a phase 3 trial as a treatment for myelofibrosis patients who are symptomatic and anemic and were previously treated with an approved JAK inhibitor.